Mori Shinichiro, Karube Masataka, Yasuda Shigeo, Yamamoto Naoyoshi, Tsuji Hiroshi, Kamada Tadashi
Research Center for Charged Particle Therapy, National Institute of Radiological Sciences, Chiba, Japan.
Br J Radiol. 2017 Jun;90(1074):20160936. doi: 10.1259/bjr.20160936. Epub 2017 May 25.
To explore the trade-off between dose assessment and imaging dose in respiratory gating with radiographic fluoroscopic imaging, we evaluated the relationship between dose assessment and fluoroscopic imaging dose in various gating windows, retrospectively.
Four-dimensional (4D) CT images acquired for 10 patients with lung and liver tumours were used for 4D treatment planning for scanned carbon ion beam. Imaging dose from two oblique directions was calculated by the number of images multiplied by the air kerma per image. Necessary beam-on time was calculated from the treatment log file. Accumulated dose distribution was calculated. The gating window was defined as tumour position not respiratory phase and changed from 0-100% duty cycle on 4DCT. These metrics were individually evaluated for every case.
For lung cases, sufficient dose conformation was achieved in respective gating windows [D-clinical target volume (CTV) > 99%]. V-lung values for 50%- and 30%-duty cycles were 2.5% and 6.0% of that for 100%-duty cycle. Maximum doses (cord/oesophagus) for 30%-duty cycle decreased 6.8%/7.4% to those for 100%-duty cycle. For liver cases, V-liver values for 50%- and 30%-duty cycles were 9.4% and 12.8% of those for 100%-duty cycle, respectively. Maximum doses (cord/oesophagus) for 50%- and 30%-duty cycles also decreased 17.2%/19.3% and 24.6%/29.8% to those for 100%-duty cycle, respectively. Total imaging doses increased 43.5% and 115.8% for 50%- and 30%-duty cycles to that for the 100%-duty cycle.
When normal tissue doses are below the tolerance level, the gating window should be expanded to minimize imaging dose and treatment time. Advances in knowledge: The skin dose from imaging might not be counterbalanced to the OAR dose; however, imaging dose is a particularly important factor.
为了探讨在放射荧光透视成像的呼吸门控中剂量评估与成像剂量之间的权衡,我们回顾性评估了不同门控窗口下剂量评估与透视成像剂量之间的关系。
将为10例肺和肝肿瘤患者采集的四维(4D)CT图像用于扫描碳离子束的4D治疗计划。通过图像数量乘以每张图像的空气比释动能来计算两个倾斜方向的成像剂量。从治疗日志文件中计算所需的束流开启时间。计算累积剂量分布。门控窗口定义为肿瘤位置而非呼吸相位,并在4DCT上从0 - 100%的占空比进行变化。对每个病例分别评估这些指标。
对于肺部病例,在各个门控窗口中均实现了足够的剂量适形[临床靶体积(CTV)的剂量覆盖>99%]。50%和30%占空比时的肺体积值分别为100%占空比时的2.5%和6.0%。30%占空比时的最大剂量(脊髓/食管)相较于100%占空比时降低了6.8%/7.4%。对于肝脏病例,50%和30%占空比时的肝脏体积值分别为100%占空比时的9.4%和12.